Modelling the effects of adherence to the HIV fusion inhibitor enfuvirtide

被引:15
|
作者
Lou, Jie [1 ]
Smith, Robert J. [2 ,3 ]
机构
[1] Shanghai Univ, Dept Math, Shanghai 200444, Peoples R China
[2] Univ Ottawa, Dept Math, Ottawa, ON K1N 6N5, Canada
[3] Univ Ottawa, Fac Med, Ottawa, ON K1N 6N5, Canada
基金
加拿大自然科学与工程研究理事会;
关键词
Enfuvirtide; Fusion inhibitors; Antiretroviral therapy; Mathematical model; Adherence; IMMUNOLOGICAL MODEL; DRUG-RESISTANCE; INFECTION; DYNAMICS; THERAPY; ENTRY;
D O I
10.1016/j.jtbi.2010.09.039
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Recently, the first drug in a new class of antiretroviral HIV drugs was approved, the fusion inhibitor enfuvirtide. We develop a mathematical model that describes the binding of the virus to T cells. We model the effect of enfuvirtide upon this process using impulsive differential equations. We find equilibria and determine stability in the case of no therapy and then when therapy is taken with perfect adherence. We determine analytical thresholds for the dosage and dosing intervals to ensure the disease-free equilibrium remains stable. We also explore the effects of partial adherence. Our theoretical results suggest that partial adherence may, at times, be worse than no therapy at all, but at other times may in fact as good as perfect adherence. It follows that patients should be counselled on the importance of adherence to this new antiretroviral drug. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 50 条
  • [1] Mathematical Modelling of Enfuvirtide and Protease Inhibitors as Combination Therapy for HIV
    Chowdhury, Sonia
    Roy, Priti Kumar
    Smith, Robert J.
    INTERNATIONAL JOURNAL OF NONLINEAR SCIENCES AND NUMERICAL SIMULATION, 2016, 17 (06) : 259 - 275
  • [2] Enfuvirtide: the first HIV fusion inhibitor
    Lazzarin, A
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (03) : 453 - 464
  • [3] Enfuvirtide, the first fusion inhibitor to treat HIV infection
    Poveda, E
    Briz, V
    Soriano, V
    AIDS REVIEWS, 2005, 7 (03) : 139 - 147
  • [4] Enfuvirtide: A fusion inhibitor for the treatment of HIV infection
    Fung, HB
    Guo, Y
    CLINICAL THERAPEUTICS, 2004, 26 (03) : 352 - 378
  • [5] Resistance to enfuvirtide, the first HIV fusion inhibitor
    Greenberg, ML
    Cammack, N
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) : 333 - 340
  • [6] HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications
    Miller, MD
    Hazuda, DJ
    DRUG RESISTANCE UPDATES, 2004, 7 (02) : 89 - 95
  • [7] Enfuvirtide: First fusion inhibitor for treatment of HIV infection
    Jamjian, MC
    McNicholl, IR
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2004, 61 (12) : 1242 - 1247
  • [8] The fusion inhibitor enfuvirtide in recent antiretroviral strategies
    Makinson, Alain
    Reynes, Jacques
    CURRENT OPINION IN HIV AND AIDS, 2009, 4 (02) : 150 - 158
  • [9] Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide
    Dingens, Adam S.
    Arenz, Dana
    Overbaugh, Julie
    Bloom, Jesse D.
    VIRUSES-BASEL, 2019, 11 (05):
  • [10] Recombinant approach for the production of HIV fusion inhibitor Enfuvirtide using Escherichia coli
    Kosana, Ravikanth Reddy
    Bajji, Chitra
    Kanumuri, Radha Madhavi
    Panati, Kalpana
    Mangamoori, Lakshmi Narasu
    Tummuru, Muralikrishna Reddy
    Narala, Venkata Ramireddy
    PROTEIN EXPRESSION AND PURIFICATION, 2014, 95 : 136 - 142